Home > Insider Trading > Filing (0001179110-12-000927)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
820237	Gen Probe Inc	GPRO	Surgical & Medical Instruments & Apparatus (3841)	330044608

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1205465	Carl Hull	Gen-Probe Incorporated 10210 Genetic Center Drive San Diego CA 92121	Chairman And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-01-17	17,083	$43.72	60,787	No	4	M	Direct
Common Stock	Disposition	2012-01-17	17,083	$60.86	43,704	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2012-01-17	17,083	$0.00	17,083	$43.72

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,917		2016-05-18	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2011.
This transaction was executed in multiple trades at prices ranging from $60.52 to $61.11. The price reported above reflects the weighted average sale price for these transactions. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the reported transactions were effected.
The amount reported includes an aggregate of 75 shares of common stock acquired under the Gen-Probe Incorporated Employee Stock Purchase Plan since the reporting person last filed a Form 4 with the Securities and Exchange Commission.
25% of the shares subject to the stock option vested and became exercisable on May 18, 2010 and the remaining shares subject to the stock option vest and become exercisable in equal monthly installments over the following three years.